BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15585509)

  • 1. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP; Taggart AJ
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
    Ferraccioli G; Gremese E
    Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF-alpha therapy as a new option in treatment of rheumatoid arthritis?].
    Leeb BF; Sautner J
    Wien Med Wochenschr; 1999; 149(19-20):554-7. PubMed ID: 10637966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Jones RE; Moreland LW
    Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis.
    Moreland LW
    Isr Med Assoc J; 2001 Sep; 3(9):686-90. PubMed ID: 11574988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
    di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
    Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC; Saxne T; Sjöholm A; Truedsson L; Jönsson G; Geborek P
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.